Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.74 |
| ▸ | FLT4 | P35916 | 4/20 | 0.65 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.65 |
| ▸ | AURKA | O14965 | 3/20 | 0.65 |
| ▸ | GSK3B | P49841 | 3/20 | 0.65 |
| ▸ | CDK2 | P24941 | 2/20 | 0.65 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.65 |
| ▸ | IKBKB | O14920 | 1/20 | 0.65 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.65 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.65 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.65 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.65 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.65 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305187 | 1.00 | CHEK1 (0.74) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL12534477 | 0.92 | CHEK1 (0.67) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL306199 | 0.91 | CHEK1 (0.68) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL306200 | 0.91 | CHEK1 (0.68) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL305717 | 0.90 | CHEK1 (0.74) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL305718 | 0.90 | CHEK1 (0.74) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL10083991 | 0.88 | CHEK1 (0.71) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL10076340 | 0.87 | CHEK1 (0.60) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL304807 | 0.86 | CHEK1 (0.68) | CHEK1FLT4RPS6KA3AURKAGSK3B | |
| SCHEMBL304808 | 0.86 | CHEK1 (0.68) | CHEK1FLT4RPS6KA3AURKAGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | claimed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093244-B2 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2330105-A1 | Heteroaryl urea derivatives useful for inhibiting CHK1 | ICOS Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | WISDOM WENDY A | 2010-01-28 | — | — | US | disclosed |
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | WISDOM WENDY A | 2010-01-28 | — | — | US | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1869020-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105262-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | CHEK1 936/4885FLT4 1516/4885RPS6KA3 778/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | CHEK1 666/4885FLT4 2351/4885RPS6KA3 918/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | CHEK1 936/4885FLT4 1516/4885RPS6KA3 778/4885 |
| US-20090143357-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PCNA | CHEK1 1/4885FLT4 3742/4885RPS6KA3 1453/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | CHEK1 666/4885FLT4 2351/4885RPS6KA3 918/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | CHEK1 1515/4885FLT4 2176/4885RPS6KA3 828/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | CHEK1 936/4885FLT4 1516/4885RPS6KA3 778/4885 |
| US-20100022512-A1 | COMPOSITIONS OF CHK1 INHIBITORS AND CYCLODEXTRIN | CHEK1, CHEK2, DDB1 | CHEK1 1/4885FLT4 3760/4885RPS6KA3 1337/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | CHEK1 1515/4885FLT4 2176/4885RPS6KA3 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.